紫金矿业（601899）(02899)涨近6%，高见38.78港元，再创历史新高。截至发稿，涨5.84%，报38.76港 元，成交额13.27亿港元。 消息面上，紫金矿业近期发布年度业绩盈喜，预计全年实现归母净利润510亿至520亿元，较上年同期的 320.51亿元增加约189亿至199亿元，同比增幅约为59%至62%。公告显示，2025年紫金矿业主要矿产品 产量全面增长，叠加矿产金、铜、银销售价格同比上涨，形成双重利好；碳酸锂业务从"零星产 出"到"规模量产"的跨越式突破。 花旗发布研报称，紫金矿业创始人兼董事长陈景河已正式退休。自其决定退休的公告发布后，尽管他仍 将担任公司高级顾问及名誉董事长，但部分投资者似乎感到担忧并选择获利了结。花旗认为这些担忧是 错置的。主要由于陈景河认为现在是将管理权移交给管理团队的合适时机，因为这是将紫金矿业从"创 始人驱动"转型为"机制驱动"的必要一步。 ...

私募投资管理业务方面，仅考虑两支在管基金退出即可收到 104 亿现金 回报；生物医药方面，预计深圳健元估值贡献约 60 亿，可参考已上市 多肽 CDMO 同类公司的估值水平。 目前四川双马市盈率（PE）对应的是 39 倍（2025）、17 倍 （2026）、13 倍（2027），基于其转型战略和潜在增长，首次覆盖给 予买入评级。 年四季度，公司以 16 亿元收购了多肽 CDMO 深圳健元，并于 2025 年参与收 购无锡生基，开始布局 CGT、CDMO 等医药先进制造领域。这些发展历程表明， 生物医药已成为公司继水泥和股权投资后的重要主营业务板块。 四川双马 20260105 摘要 四川双马通过 IDG 入主转型，从单一水泥企业发展为股权投资和生物医 药双主业公司，持续剥离水泥资产，并积极布局生物医药领域，如收购 深圳健元和参与收购无锡生基。 市场对四川双马的股权投资业务兑现存在不确定性预期，认为其生物医 药业务贡献较小，限制了整体估值提升，特别是首批基金进入退出期， 管理费收入可能下滑。 公司股权投资业务退出收益确定性高，IDG 资本管理能力突出，多个硬 科技项目成功 IPO 或排队中，预计和谐景裕、和谐景 ...

Core Insights - Heavy insider buying by top executives and directors at Nike signals potential confidence in the company's turnaround efforts as Wall Street reassesses its future [3][6] - Nike's stock price increased by 4.12% to close at $63.71, with trading volume significantly above its three-month average, indicating heightened investor interest [2][6] - Despite a challenging year with a nearly 16% decline in 2025, Nike's stock has seen an 11% increase in the past five days, reflecting a positive shift in market sentiment [6] Company Performance - Nike's market capitalization stands at $90 billion, with a gross margin of 41.98% and a dividend yield of 2.63% [2] - The company's stock has experienced a significant growth of 35,355% since its IPO in 1980, showcasing its long-term value creation [3] - CEO Elliott Hill increased his stake by over 7% in a transaction exceeding $1 million, while board member Tim Cook purchased around $3 million worth of shares, further indicating confidence in the company's direction [6][7] Industry Context - The athletic footwear and apparel industry is facing challenges, with competitors like Adidas and Puma experiencing slight declines amid tariff and demand pressures [5] - Analyst sentiment towards Nike remains mixed, although Guggenheim has reiterated a Buy rating, suggesting some analysts see potential in the company's strategy [7]

证券日报网讯12月30日，光线传媒（300251）在互动平台回答投资者提问时表示，公司新办公楼目前正 在装修以匹配实际办公需求，如办公地址发生变更，公司将按照相关规则及时履行信息披露义务。公司 此次转型是一项系统性的长期战略，目前各项相关工作均在有序推进中。 ...

2024年8月26日，深交所发出公告，上市12年的首航高科，正式退出A股。 早年的黄文佳，就是个走街串巷卖水暖配件的小贩，凭着能吃苦、肯琢磨，慢慢摸清了门道。后来他转 行做五金电器贸易，这才赚下了自己的第一桶金。 到了1997年，黄文佳带着侄子黄卿乐一起，创办了首航波纹管公司，就这么开启了一家人一起创业的模 式。 作为全国能源行业里，首屈一指的明星企业。几乎没人能想到，它在退市时竟然会搞得，如此惨烈。 30多个跌停，股价暴跌至0.37元，14万股民近乎血本无归，就连国资也是牢牢被套。 几乎所有的股东都赔了个底掉，可唯独首航高科背后的黄氏家族，却是提前成功离场，还顺带套现了24 个亿。 那么，他们到底是如何玩转的这个把戏？而他们黄氏一家，如今又在何方呢？ 黄氏家族的发家史 2001年到2006年这几年，这家人踩准了电力行业发展的好时候，把生意拓展到了通风设备领域，专门做 电站的空冷系统。 那时候，这个领域的核心技术都被国外公司攥在手里，国内企业只能靠进口。 黄氏家族咬着牙投钱搞研发，最后还真打破了国外的技术垄断，让首航的空冷系统在国内市场站稳了 脚。 最火的时候，他们的市场份额占到了22%，订单接都接不过来，公 ...

Core Insights - Apple CEO Tim Cook recently purchased 50,000 shares of Nike at an average price of $58.97, totaling nearly $3 million, which nearly doubles his stake in the company [4] - Nike has faced significant challenges, including a 19% stock decline this year and over 57% in the past five years, attributed to rising competition, price-sensitive consumers, and macroeconomic factors [1][2] - The company acknowledged strategic mistakes, such as overemphasis on online promotions and lack of product innovation, but is currently undergoing a turnaround plan [2][8] Financial Performance - Nike reported earnings of $0.53 per share on revenue of $12.4 billion for Q2 of fiscal year 2026, exceeding Wall Street estimates [6] - Despite strong earnings, the stock price fell due to disappointing guidance, particularly regarding performance in China, a key market for Nike [6][7] - Nike is guiding for low single-digit percentage revenue decline in Q3, with ongoing challenges in Greater China and the Converse brand [7][8] Strategic Challenges and Initiatives - Nike's turnaround plan focuses on a renewed emphasis on athletes, brand identity, and product innovation, with some positive traction noted in North America [8] - The company faces significant challenges in China, needing to better connect with consumers and efficiently reach them [9] - Investors are advised to be patient as the turnaround may take time, but the presence of notable investors like Tim Cook may instill confidence [10]

Core Viewpoint - The management of Lino Pharmaceutical has explained the recent adjustments in leadership, performance fluctuations, and shareholder reductions, emphasizing the company's commitment to long-term development and strategic transformation [1][2]. Group 1: Management Adjustments - The management changes at Lino Pharmaceutical occurred mainly in October and December, including the resignation of the former chairman and other board members, with a focus on optimizing governance and enhancing organizational vitality [1][2]. - The adjustments are described as proactive, considering personal intentions and the need for governance structure improvement, aligning with new legal requirements [2]. Group 2: Performance and Strategic Investments - The company acknowledges that short-term performance pressures are a result of a "growing pains" phase during its transformation, reflecting significant strategic investments in high-barrier products [3][4]. - Lino Pharmaceutical is focusing on high-tech pharmaceutical packaging, particularly in innovative products like borosilicate molded bottles and pre-filled syringes, which are essential for enhancing core competitiveness and long-term positioning [3][4]. Group 3: Long-term Vision and Shareholder Dynamics - The company is committed to bearing the costs of transformation, including increased investments in market expansion, R&D, and talent acquisition, viewing these as necessary for future growth despite short-term profit pressures [4]. - The recent shareholder reductions are attributed to normal market behavior related to fund cycles and employee stock plans, with the core management team not participating in the reductions, indicating a strong alignment of interests between management and the company's long-term goals [4][5].

对于短期业绩压力，公司表示这是转型升级中的"阵痛期"，公司自上市后，战略重心明确锁定在技术门 槛更高的医药包装领域，特别是中硼硅模制瓶、预灌封注射器、RTU等代表行业未来发展方向的创新型 产品。这类大规模、方向清晰的资本投入，是提升公司核心竞争力、布局长远的关键举措。对于新增产 能效益释放周期较长的问题，公司指出这主要源于医药包材行业严格的监管与客户认证流程，随着产能 的逐步释放以及下游市场开拓的逐步达成，盈利状况将得到恢复。 公司持续强化研发与人才储备，在市场拓展和研发创新方面的持续高投入，是公司确保技术领先性和未 来增长动能的直接努力。即使在财务压力下，公司仍坚持投入，显示了其以创新驱动发展的坚定信念。 据了解，力诺药包近期的人员变动是综合考虑个人意愿、岗位职能变化及治理结构完善的主动调整。尤 其是为顺应新《公司法》等法规要求，公司在调整董事会结构时，不仅完成了程序上的优化，更重要的 是将原具有丰富履职经验的监事及职工代表转为董事，强化了公司治理中的制衡机制与内部监督。此 外，原副总经理转赴海外专注重点项目建设，也是公司资源向战略性项目精准配置的体现。 团队年轻化与专业化是现代化公司团队管理的重要方向，本 ...

申科股份公告称，为加快转型，提升制造及服务能力，优化产能布局，公司拟在山东枣庄设立全资子公 司山东申科动力装备有限公司，注册资本2000万元。公司于2025年召开董事会审议通过该议案，投资在 决策权限内，无需股东会批准。公司持股100%，法定代表人为张晓非。出资为货币资金，来源为自有 或自筹。该投资预计对财务无重大影响，但面临多种不确定风险，公司将积极应对。 ...

Embattled BP made a dramatic CEO change Wednesday as it hired Woodside Energy leader Meg O’Neill as the first-ever woman CEO of a Big Oil giant. O’Neill is a Colorado native and Exxon Mobil veteran who grew Australia’s Woodside into a much bigger global natural gas player with expansions into the U.S. She is taking over the British energy behemoth at a time when it has fallen behind the other global oil and gas supermajors and was even a potential takeover target earlier this year by rival Shell. Curren ...